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Abstract. There is growing interest in using fluorescence imaging instruments to guide surgery, and the leading
options for open-field imaging are reviewed here. While the clinical fluorescence-guided surgery (FGS) field has
been focused predominantly on indocyanine green (ICG) imaging, there is accelerated development of more
specific molecular tracers. These agents should help advance new indications for which FGS presents a para-
digm shift in how molecular information is provided for resection decisions. There has been a steady growth in
commercially marketed FGS systems, each with their own differentiated performance characteristics and spec-
ifications. A set of desirable criteria is presented to guide the evaluation of instruments, including: (i) real-time
overlay of white-light and fluorescence images, (ii) operation within ambient room lighting, (iii) nanomolar-level
sensitivity, (iv) quantitative capabilities, (v) simultaneous multiple fluorophore imaging, and (vi) ergonomic utility
for open surgery. In this review, United States Food and Drug Administration 510(k) cleared commercial systems
and some leading premarket FGS research systems were evaluated to illustrate the continual increase in this
performance feature base. Generally, the systems designed for ICG-only imaging have sufficient sensitivity to
ICG, but a fraction of the other desired features listed above, with both lower sensitivity and dynamic range. In
comparison, the emerging research systems targeted for use with molecular agents have unique capabilities that
will be essential for successful clinical imaging studies with low-concentration agents or where superior rejection
of ambient light is needed. There is no perfect imaging system, but the feature differences among them are
important differentiators in their utility, as outlined in the data and tables here. © The Authors. Published by SPIE
under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of
the original publication, including its DOI. [DOI: 10.1117/1.JBO.21.8.080901]
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1 Introduction
In recent years, there has been an explosion of interest in fluo-
rescence-guided surgery, which has led to a steady demand for
new commercially developed and approved fluorescence imag-
ing devices. For the greatest clinical impact, an imaging system
needs to provide a solution to the immediate clinical goal with
important new information that affects the patient outcome in a
way that seamlessly blends into current clinical workflow. There
are several new fluorescence imagers that have been cleared for
the market by the 510(k) process at the United States Food and
Drug Administration (FDA) for open-surgical use with indocya-
nine green (ICG). Beyond this, new commercial research
systems with important features are regularly emerging. How-
ever, there is often a disconnect between this emergent technol-
ogy and the surgeons’ needs and flexibility.1 Several reviews
discuss the design, applications, and need for such imagers
and tabulate the specifications of available imagers in the
market.2–7 However, none of them provides direct guidance on
how to choose the right imager based on objective criteria.
System selection can be subjective and dependent on the
end-user’s preferences; however, defining basic criteria for
comparing imagers for specific applications can help the field
of surgical-guidance mature in an organized manner.
The exponential growth in the field is demonstrated by the
total number of published articles in the area of fluorescence-
guided surgery (FGS), which has grown from under 50/year
in 1995, to 100/year in 2005, and to nearly 500/year in
2015. This growth is almost equally divided between papers dis-
cussing the growing clinical imaging approaches with ICG8 and
the growing development of targeted-molecular contrast agents
for specific vascular, metabolic, or immunologic features of tis-
sue, by the research community.4,9 While most ICG imaging has
been performed by use of the Novadaq SPY system as it was the
first to be approved in 2005, several new systems have gained
510(k) clearance in the last 2 years, as shown in Table 1. These
are all approved for procedures involving imaging blood flow,
tissue perfusion, and transfer circulation in free flaps, plastic sur-
gery, and reconstructive surgery. Despite the availability of these
technologies, most surgeons still rely largely on visual and tac-
tile cues combined with presurgical radiologic imaging to guide
tissue resection. The potential benefit to surgical patients for
improving tissue identification based on molecular differences,
*Address all correspondence to: Alisha V. DSouza, E-mail: alisha.v.dsouza@
dartmouth.edu; Brian W. Pogue, E-mail: brian.w.pogue@dartmouth.edu
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particularly to those undergoing removal of cancers, is a com-
pelling force driving the research and development in the field of
FGS. Using molecular signals in the surgical field is a natural
progression that follows the development of molecular pathol-
ogy to identify lesion phenotype in conjunction with image
guidance from MRI or CT, as a decision tool for patient man-
agement; there is a compelling evidence that these phenotypes
can be imaged in vivo to allow better real-time definition of the
surgical margin.10–16
In addition to ICG, there is extensive ongoing research
using fluorescein and 5-aminolevulinic acid-induced protopor-
phyrin IX (PpIX) imaging for neurosurgery,17–21 a procedure that
has gained clinical approval in a handful of countries (Approved
by the European Medicines Agency in September 2007 and is
approved for use in all European Union, European Economic
Area, and European Free Trade Association states). Additionally,
PpIX fluorescence imaging using blue light illumination has local
approvals in some countries for subspecialty use in bladder cancer
detection22–24 and gynecologic oncology25–27 with clinical trials
underway. These fluorophores are FDA approved for certain
indications and emit fluorescence within the visible light
range; therefore, existing surgical microscopes can be modified
with some basic filters to allow surgeons to switch back and
forth between white-light and fluorescence modes. However,
while there is apparently good sensitivity, the lack of high speci-
ficity of PpIX in some indications has limited the widespread
adoption of this endogenous metabolic fluorophore. Moreover,
the emission bands correspond to the visible light window and
hence suffer from high background autofluorescence. The high
absorption from biological chromophores in the visible light
window also limits sensitivity to these fluorescence emissions
at depth allowing only surface imaging. Near-infrared (NIR) flu-
orophores, on the other hand, emit in a wavelength window with
very low tissue autofluorescence, and also have greater penetra-
tion depth due to the reduced hemoglobin absorption in the 650-
to 900-nm range.28 Available within this range is methylene
blue, a weakly fluorescent visible blue dye that is currently
approved for use as a visible stain for lymph node mapping.2
While some research groups have investigated its use as a
far-red fluorophore,29 the low fluorescence yield and lack of
any functional groups for addition of ligands have limited its
use in clinical applications. ICG is the only approved fluoro-
phore in the NIR-window and several imagers have been
designed and commercially launched to allow ICG guidance
in surgery for blood flow assessment,30–32 hepatic function
assessment,33,34 and vessel patency and perfusion evaluation
especially in reconstructive35,36 and bypass surgeries.37,38 The
low tissue autofluorescence in the NIR-wavelengths further sim-
plifies the task of filtering out background signals, and since
ICG is the primary reimbursable agent today, almost all imaging
device companies have built systems specifically for ICG imag-
ing. Currently, there is growing use of ICG in off-label and
investigational applications such as lymphatic imaging39 and
surgical procedures such as sentinel lymph node identification
and mapping.40–42 Yet a strong motivation for future develop-
ment in the field is to achieve the potential for imaging molecu-
lar tracers that report on new vascular, structural, metabolic,
immunologic, or genetic features of the tissue.43
Surgical oncology is in a position to benefit greatly from
fluorescence imaging technology, and targeted-molecular surgi-
cal guidance in particular, is poised to follow the widespread
adoption of molecular pathology phenotyping.4 Several
Table 1 FDA clearances through the 510(k) process based on the device being safe and effective, with substantial equivalence to a predicate
device. These are all ICG fluorescence imaging systems shown along with their year of premarket approval by FDA, case number, and the
indications that they are approved for.




number Indication approved for
Novadaq Technologies, Inc. SPY imaging system 2005 K042961 Blood flow
Novadaq Technologies, Inc. SPY imaging system SP2000 2007 K063345 Tissue perfusion and transfer
circulation in free-flaps, plastic,
and reconstructive surgery
Novadaq Technologies, Inc. SPY fluorescent imaging system SP2001 2008 K073088 510(k) with SPY SP2000
Novadaq Technologies, Inc. SPY fluorescent imaging system SP2001 2008 K073130 510(k) for modified device
Novadaq Technologies, Inc. SPY intraoperative imaging system 2011 K100371 Additional gastrointestinal imaging
Hamamatsu Photonics K.K. PDE photodynamic eye 2012 K110480 510(k) with SPY K063345 and
K073130
Hamamatsu Photonics K.K. PDE Neo 2014 K133719 510(k) with PDE K110480 for
modified device
Fluoptics Fluobeam 800 clinical imaging device 2014 K132475 510(k) with PDE
Quest Medical Imaging Artemisa light engine 2015 K141164 510(k) with Karl Storz and Olympus
Winter
Quest Medical Artemisa handheld imaging systems 2015 K143474 510(k) with PDE and Fluobeam 800
VisionSense Ltd. VS3-IR-MMS system 2015 K150018 510(k) with SPY 063345
aThe Artemis system is now called Quest Spectrum.
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companies are now producing NIR-emitting agents that can be
imaged using systems designed for ICG, but with substantially
higher fluorescence yields than ICG, and availability of mole-
cules that can be conjugated to targeting moieties for future
indications that have molecular specificity: IRDye 800CW
(LI-COR Biosciences, Lincoln, NE), ZW800-144 (Curadel
ResVet Imaging, Worcester, Massachusetts), and VivoTag 800
(PerkinElmer, Hopkinton, Massachusetts). As applications
emerge with specific agents designed for molecular diagnostic
imaging, the sensitivity and dynamic range requirements will
vary greatly from the current paradigm of ICG flow
imaging—typical ICG studies are performed with mg/ml level
concentrations in the blood, whereas molecular probes are
typically imaged at μg∕ml to ng/ml concentration levels. The
sensitivity along with the interplay of various factors that affect
system performance such as ambient room lighting, image
threshold and visualization, ultimately decide the apparent sig-
nal-to-background ratio (SBR) performance of a system within
the surgical environment. Using systems in a “real-time” mode
that display the fluorescence signal in a video feed imposes
restrictions on the system sensitivity. This is particularly true
in open surgery in which the operation is conducted under bright
lighting; this is less of a challenge in minimally invasive surgery
in which the procedure can take place in a darkened room. The
lack of professional society guidance or standard documents on
system quality and accuracy assessment further complicates
matters, as there is no single test to compare systems under
standard conditions as yet, and hence any SBR performance
limitations are established based on clinical trials. Several
research groups have been discussing the challenges in defining
standardized testing platforms and have been working toward
designing appropriate phantoms;45 these advancements will pave
the way for establishment of sensitivity limits of systems and
improve our understanding of their utilities in studies involving
microdoses of tracer administration.
While system sensitivity is critical for microdose-level tracer
administration, this requirement is not as important in ICG im-
aging. Trade-offs that sacrifice SBR in favor of functional utility
result in a more usable and flexible device. However, several
FDA-approved commercial imagers do not yet have the ability
to simultaneously capture and register white-light and fluores-
cence images, or operate reliably under operating room light
conditions. This limitation requires the surgical team to switch
between viewing the imager display and the surgical field, mak-
ing fluorescence imaging cumbersome and limited in its ability
to accurately register fluorescence-labeled tissues with what is
seen with visible light; the surgeons now need to mentally regis-
ter the while-light illuminated field in front of them, with the
fluorescence intensity image devoid of major anatomical land-
marks. Furthermore, providing information in a useful manner is
often an understated requirement for the successful design and
use of such imagers. While the current FDA-approved systems
have been instrumental in launching fluorescence-guided surgery
into growing clinical use, we believe that identifying the most
important basic requirements from fluorescence imagers must
be re-evaluated to address the unmet needs through future systems
that are currently in the developmental phase. Figure 1 shows a
panel of figures demonstrating the use of fluorescence imaging,
and progression of fluorescence imaging devices with custom
devices leading the way and FDA approved following along.
In this review paper, we describe the key engineering
design criteria and the desirable features of a fluorescence
guidance system for open-surgical use; this discussion of desir-
able features is supplemented with a description of system
instrumentation in the sections that will follow. The current
available commercial imagers are compared in tables on the
basis of functionality, usability, and technical specifications.
Fluorescence microscopy systems, including surgical micro-
scopes and confocal microscopes, were outside the scope of
this review of open wide-field imagers and have not been dis-
cussed herein because the technological goals and functionality
of these are quite different from open-surgical systems.
2 System Uses and Feature Goals
The overall goal of every fluorescence imager is to provide
information on the distribution of the weak (relative to white-
light reflectance) fluorescence signal within the surgical field.
Clinical compatibility is improved by providing the information
in a user-friendly, distraction-free manner, while minimizing
background signals and noise. This can be simplified to the
singular goal of maximizing the SBR to distinguish between
diseased versus disease-free tissue or to identify tissue to save,
such as nerves and blood vessels, among tissue being resected.
However, SBR on its own does not make a system description
complete and does not mean much without the right means to
convey this information to the user. Achieving high SBR in a
surgical environment is a complicated problem influenced
largely by the level of ambient lights. Surgeons rely on visual
information to identify landmarks and are trained to identify tis-
sues in their native pink-red hues; any additional fluorescence
information, especially that from outside the visible range of the
light spectrum, must therefore be coregistered to the white-light
field. These issues lead to the need to be able to view both white-
light RGB and fluorescence images in real time on a display.
Furthermore, operation rooms are well-lit spaces, and imagers
that operate only in low light will have limited adoption in
most clinical procedures.
As the field of fluorescence imaging for guidance during
open surgery moves toward adoption of targeted-fluorescent
probes and the quantification of disease biomarkers,9 the tech-
nical performance demands of fluorescence imagers will
increase. While reliable absolute quantification in an open setup
has not yet been fully realized and is challenging to achieve,
there have been significant advances in ratiometric methods,
in which tracer combinations were used to quantify receptor
and molecular concentrations.48,49 There has also been recent
growth in the development of diagnostic agents that would be
administered at microdoses as compared to therapeutic agents,
to match the receptor concentrations available in tissue. This
latter issue would demand high sensitivity of fluorescence detec-
tion of probes present in the nanomolar concentration range.
Based on these needs, a listing of key desirable features of
an open fluorescence imager is as follows:
i. Real-time overlay of white-light reflectance and
fluorescence images;
ii. Fluorescence-mode operation with ambient room
lighting present;
iii. High sensitivity to tracer of interest;
iv. Ability to quantify fluorophores in situ;
v. Ability to image multiple fluorophores simultaneously;
and
vi. Maximized ergonomic use.
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To fully appreciate the complexity of enabling all these
features, a discussion of current instrumentation is necessary;
this is provided in Sec. 3. We then discuss each of the above
listed features in detail in Sec. 4.
3 Imaging System Components and
Instrumentation
The basic components of a fluorescence imager are (i) spectrally
resolved light source(s), (ii) light-collection optics and filters,
(iii) camera(s), (iv) instrument control, acquisition, and display
software, and (v) computing, input, and display hardware.
3.1 Excitation Light Source
Choice of excitation light source is based on the spectral band-
width, solid angle of output beam, output efficiency, and
regulatory considerations. Commonly used excitation sources
are (i) filtered broadband lamps, (ii) laser diodes, and
(iii) light-emitting diodes (LEDs). Ease of filtering at detection,
illumination of large field of view (FOV), output fluence rate,
mounting requirement, and cost are the main factors that influ-
ence the choice of excitation source type. Among available
options, filtered lamps have the lowest efficiency, largest spec-
tral bandwidth, and largest solid angle, and hence least spatial
















































Fig. 1 (a) Demonstrates the progression of systems in terms of their regulatory approval status along
with parallel technologies. On the left, research-grade surgical fluorescence imagers, preclinical devices,
and microscopy devices have served as contributors to the development of open-surgery fluorescence
devices. On the right, the related commercial technologies, such as endoscopic imagers, multimodal
imagers, and surgical microscopes, are specialized technologies that have greatly benefited from
advancement in open-surgery fluorescence imagers. The central arrow illustrates the technological pro-
gression of imagers with FDA-approved systems at the trailing end, and customizable devices leading
the technology development. (b)–(g) Show examples of surgical fields paired with white-light reflectance
(up) and fluorescence images (bottom) shown for various applications.10,46,47 Panels (b) and (c) show
white-light and fluorescence images, respectively, from the first in-human example of in situ ovarian
cancer delineation using folate receptor-α targeted-fluorescent agent (reprinted by permission from
Macmillan Publishers Ltd., Nature Medicine,10 copyright 2011). Panels (d) and (e) show white-light
reflectance and white-light reflectance with pseudocolor fluorescence overlay, with Fluorescein-NP41
highlighting the peripheral nerves (reprinted by permission from Macmillan Publishers Ltd., Nature
Biotechnology,46 copyright 2011). Panels (f) and (g) show ureters highlighted by methylene blue
fluorescence, reprinted from Matsui et al.,47 with permission from Elsevier.
Journal of Biomedical Optics 080901-4 August 2016 • Vol. 21(8)
DSouza et al.: Review of fluorescence guided surgery systems: identification of key performance. . .
output photons is rejected at the excitation filter resulting in high
heat dissipation, thus making their use cumbersome and subop-
timal. Such excitation source setups are seen currently in surgi-
cal microscopes.
Laser diodes have the highest spatial and spectral confine-
ment of all sources. The low spectral bandwidth allows maxi-
mum excitation light filtering at the fluorescence detection
camera. High-power options are available to deliver the best
light fluence rate for low fluorophore concentrations, but safety
concerns related to maximum permissible exposure limits for
skin and eyes complicate the regulatory approval of systems
that use these. Moreover, beam expanders would be necessary
to ensure illumination of large FOVs. Laser diodes also require
precise temperature and current control to ensure fidelity of the
output spectrum and power, thus necessitating additional hard-
ware, and remote mounting away from the patient. Such systems
would use fiber coupling from the light source to the illumina-
tion head. These are seen in the Fluobeam and Curadel Lab-
Flare systems.
LEDs provide a trade-off among output power, efficiency,
cost, and spectral bandwidth. With the growth of the LED mar-
ket, it is becoming increasingly economical to produce high-
power LEDs. To ensure homogeneity of the excitation field,
LEDs would need to be combined into an array. However,
one of the major drawbacks of using LEDs is that when fluo-
rophores with small Stokes shifts are used, there will be leakage
of excitation light past the emission filter leading to reduced
SBR. An excitation filter would thus need to be used to confine
the output of the light source. Some of the newer imagers such
as PerkinElmer Solaris and SurgVision Explorer Air system uti-
lize LED-based excitation, and we should expect to see further
increase in their use.
3.2 Collection Optical Components and
Emission Filters
Multiple trade-offs exist when discussing collection optics.
These are FOV size, depth of field, lens F-number, and operat-
ing distance. Collection optics may be designed for fixed mag-
nification or variable magnification depending on the need to
have variable field size and operating distance. Most common
imagers have a working distance of 10 to 30 cm with a maxi-
mum FOV size of about 15 × 15 cm2, but the tolerance for focus
errors varies among manufacturers and end users.
Emission filter design and choice are critical in maximizing
detection sensitivity by limiting background light. Filter choice
is influenced by spectral overlap among the reflected excitation
light, ambient lighting, and the Stokes shift of fluorophore of
interest. Fluorophores with large stokes shift such as PpIX,
which can be excited in the blue range (∼405 nm) and detected
in the red range (∼635 nm), pose few problems, whereas those
that have significant overlap between absorption and emission
spectrum such as ICG, require more careful selection (See
Fig. 3). Longpass, bandpass, and notch filters are broadly the
categories for selection. Interference filters generally provide
superior out-of-band rejection and transmission in the passband
as compared to absorption-based filters. Spectral characteristics
of filters also vary with incidence angle of light and there will be
transmission of undesirable excitation light at high incidence
angles. This along with the excitation leakage through the rejec-
tion band determines the noise floor of a device and hence
affects its sensitivity.
3.3 Imaging Sensor
The factors that influence detection performance of the camera
are dynamic range, read-out rates, pixel resolution, and on-chip
gain. For quantitative imaging, bit depths of 10-bit or more are
desirable to provide signal detection of 2 to 3 orders of magni-
tude while maintaining a low noise floor. Charge-coupled device
(CCD)-based cameras are used in fluorescence imagers almost
ubiquitously, but suffer from low quantum efficiency in the far-
red and NIR-wavelength range and slow read-out time (<30 Hz).
They can achieve low read-out noise when cooled, generally
have high resolutions, and can be used with 16-bitA∕D convert-
ers. Further improvements in sensitivity are achievable with
electron multiplied-CCDs (EMCCD) and intensified-CCDs
(ICCD); these can provide analog gains of over 1000× and
are of benefit when signal intensity is very low, but signal qual-
ity can degrade at high noise levels; these trade-offs would need
to be considered carefully. The available quantum yield of sen-
sors in the far-red- and NIR-wavelength regime can drop off
significantly from the visible region, and this too will affect
appropriate camera/sensor selection on a system. Almost all
commercial fluorescence imagers use CCD cameras and the
SurgVision system uses an EMCCD camera. The scientific-
CMOS (sCMOS) cameras are now a contender against CCD
cameras as they provide high read-out rates, high bit depth,
and the specific advantage of many more pixels per frame. In
addition to the high read-out rate and high bit depth, the compact
size, light weight, and low read-out noise make sCMOS cameras
the sensor of next-generation fluorescence imagers. One of the
drawbacks, however, is the higher cost as compared to standard
CMOS technology. Among the commercial systems available,
the PerkinElmer Solaris is the only system that uses an sCMOS
camera. More sophisticated camera configurations such as mul-
tispectral cameras, though rarely used in most systems, will be
discussed briefly in Sec. 4.1.
3.4 Software Control, Computing, Data Storage,
and Display Hardware
Software designs vary in the degree of user customizability;
those that target clinical use generally have the least flexibility
while investigational systems and research-oriented systems
allow a good deal of user customization. With growing bit
depths, high-speed data transfer and data storage become impor-
tant considerations. Imaging and storing large video sequences,
potentially from multiple cameras, can result in several giga-
bytes of imaging data per hour—storing one hour of single
channel 1024 × 1024 pixel2 8-bit fluorescence data at 30 fps for
an hour would need >100 GB of space—posing a significant
data management challenge. One approach to tackle this is to
store compressed video files only and save data into an 8-bit
format, even if the camera provides >10-bits per pixel. Alterna-
tive strategies include saving user-prompted snapshots from a
continuous video stream. The ability to customize storage and
export on to external drives or servers may be a solution as well,
but local protected storage is likely the best candidate for clinical
systems to maintain Health Insurance Portability and Account-
ability Act compliance. However, data storage may be critical in
research settings, to allow postprocessing, and image analysis
postacquisition. Systems such as the PDE Neo lack on-board
storage options and provide only screen captures, which is non-
ideal and nonquantitative.
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As devices grow in sophistication, software control of instru-
ments becomes more complex especially when multicamera
systems are used. On-board GPUs are often necessary for simul-
taneous overlay and streaming. It is important that systems be
customizable yet easy to use for clinical staff and surgeons. The
software functionality also directly ties-in with data visualiza-
tion and display optimization. Need for ROI intensity measure-
ment tools, and on-screen window-level and compression
options50 will increase as systems are used for quantitative or
semiquantitative imaging, and as image bit depths exceed the
display bit depths. Software design is the most understated
aspect of fluorescence imagers, but since their use during sur-
gery would need seamless integration with the surgical protocol,
robust, intuitive design is key.
4 Design Goals and Analysis of Key Features
4.1 Real-Time Overlay of White-Light Reflectance
and Fluorescence Images
Most FDA-approved imagers, such as Novadaq SPY,
Hamamatsu PDE Neo, and Fluoptics Fluobeam 800, are single
channel fluorescence video/image display systems. However,
imagers that have the ability to provide the fluorescence
image overlaid on a white-light illuminated RGB image in a
real-time video stream would provide richer and more complete
information to a surgeon/user. To produce such images in real
time is significantly more complex than a single channel fluo-
rescence video stream. While there are several approaches for
achieving overlaid data, wavelength-based separation of fluores-
cence (>650 nm) and visible white light (<650 nm) is the main
principle upon which imager designs are based.
The most commonly employed technological approaches for
achieving simultaneous white-light and fluorescence imaging
are use of beam splitters and multiple cameras or multispectral
cameras that separate visible and far-red and/or NIR-wave-
lengths within the camera itself using prisms and multiple CCD
or CMOS sensors. The Flare intraoperative prototypes from the
Frangioni laboratory use three cameras,41 and Curadel’s Lab-
Flare imager, based on the Flare prototype, uses three CCD
sensors within a single camera body to simultaneously image
two fluorescence channels and a white-light RGB channel,
by removing the ∼800-nm (NIR) fluorescence component,
the ∼700-nm far-red fluorescence component, and using the
remainder to produce the RGB image, as shown in Figs. 2(b)
and 2(d). The Quest Spectrum system (previously called
White-light color




White-light + Pseudocolor  
Fluorescence White-light-reflectance color image
Fig. 2 Shows various white-light and fluorescence overlay schemes. (a) Shows a screenshot from
the PerkinElmer Solaris imager during lymphatic imaging (image courtesy of PerkinElmer). The imaging
windows display white light and the fluorescence overlaid on the white-light images simultaneously. User
processing controls, such as ROI and display gain adjustments, are also available. (b) Shows the com-
monly used wavelength-based separation of collected light using dichroic mirrors and filters as seen in the
Flare prototype system (reprinted from Troyan et al.41 with permission of Springer), Curadel Lab-Flare uses
a similar setup with slightly different wavelength specifications on beam splitters and emission filters.
(c) The modified Bayer filter is an alternative approach to perform simultaneous NIR detection, though
this approach limits the active area for the fluorescence channel, reducing sensitivity.51 (d) Shows an
example of simultaneous imaging and display of 700-nm (red) and 800-nm (green) fluorescence channels
from the Flare prototype with the mesenteric lymph nodes highlighted by methylene blue (brackets) and
a sentinel node (arrow) highlighted by ICG, reprinted from Troyan et al.41 with permission of Springer.
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Artemis) achieves similar wavelength-based separation using
prisms within a single camera, and can simultaneously image
and overlay two NIR channels (700 to 830 nm and 830 to
1100 nm) on the white-light RGB image stream. However,
expansion to more channels would require additional cam-
eras/sensors for simultaneous acquisition. VisionSense Iridium
also uses two CCD sensors to produce simultaneous white-light
RGB and NIR fluorescence images from the ∼800-nm emission
channel and merges the two in real time. These approaches work
well in practice, allow independent gain adjustments for each
channel, and do not require sequential pulsing of excitation
lights. The SurgVision and PerkinElmer Solaris systems, on
the other hand, feature two cameras, one for white-light image
acquisition and one for fluorescence acquisition, with overlay
capability. A screenshot of the Solaris display in Fig. 2(a)
shows “white-light RGB” and “white-light RGB + fluorescence
overlay” images showing fluorophore uptake in murine lymph
nodes. Additional considerations for multicamera setups include
coregistration of the various video streams and magnification
corrections. For example, Novadaq SPY uses two cameras that
are not coregistered and have different pixel dimensions and
zoom, as such no overlay functionality has been implemented,
and white-light images are available only in snapshot mode.
Other related approaches employ Foveon X3 sensors
(HyperEye Medical System, Mizuho Medical, Japan)52 to detect
unabsorbed NIR light or modify the Bayer filter pattern and
filter the NIRF signal at the entrance to the sensor,51 thus sep-
aration happens within the camera itself [see Fig. 2(c)]. These
approaches, while overcoming the problem of merging multiple
streams, can be limited in their sensitivity to weak fluorescence
emissions, which is most significant for targeted tracers at low
concentrations in tissues.
The optimization of fluorescence visualization and displays
is often underreported as systems are only now beginning to
exploit overlay-based displays. With the growth in use of 10-
to 16-bit acquisition cameras, proper scaling and mapping of
displays on traditional display monitors are an additional
concern. Application of appropriate transparency functions to
the fluorescence overlay, choice of appropriate colormaps, and
need for compression50 techniques to display high bit depth
images are important areas with only limited discussion in
the literature. The field of high dynamic range (HDR) imaging
has allowed optimal display of HDR data, yet this approach has
not penetrated into medicine much as of today. As fluorescence
imagers incorporate simultaneous multiple channel imaging,
this aspect will gain greater importance. Elliott et al.53 provide
a set of guidelines for effective visualization of fluorescence dur-
ing surgery using surgical microscopes, which are applicable to
open surgery as well.
4.2 Fluorescence-Mode Operation with Ambient
Room Lighting Present
For an imaging system to be easily translatable into a surgical
suite or clinical environment, it is desirable that it operates under
room lights and provides reasonable SBR. This issue is critical,
especially when working with low fluorophore concentrations
and when quantitation is necessary. Figure 3(e) shows a plot of
the most common room light sources, such as tungsten bulbs,
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Fig. 3 (a)–(d) The chemical formulas are shown along with absorption and emission spectra of the major
FDA-approved fluorescent dyes such as fluorescein, PpIX, ICG, and methylene blue. (e) The normalized
emission spectra are shown for common light sources used in surgery.
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halogen bulbs, compact fluorescence lights, and the newer
LED lights. It can be seen that tungsten and halogen lamps
have significant output in the 600- to 850-nm range and may
thus contribute a major portion of the detected signal during
any red to NIR fluorescence imaging. Use of these lamps in
rooms is seeing a declining trend, to the ultimate benefit of
fluorescence imagers. As a general guideline for researchers
and other users of such systems, use of tungsten and halogen
lamps, or sunlight, should be avoided completely. Both
LEDs and compact fluorescent lights (CFL) have minimal signal
contribution over 780 nm and thus imaging of ICG and similar
NIR fluorophores in rooms lit with these sources should be
attainable with simple filtering techniques. However, it should
be noted that CFL lights can often emit in the 700- to 800-nm
wavelength range during the warm-up phase, which can last 5 to
10 min (data not shown), and thus contamination of detected
fluorescence can occur at these times. For imaging fluorophores
in the visible to far-red window, i.e., 500 to 750 nm, normal
room lighting would contribute to the detected signal and
sophisticated background removal methods are necessary.
Pulsing the LED or laser diode excitation light sources in a man-
ner that is synchronized to a gated- or shuttered-detector system,
such as CMOS or ICCD camera,54 is one technique that may be
employed to address background contamination. Similar back-
ground mitigation can be achieved using frequency modulation
and lock-in detection.55 Finally, additional considerations, such
as operating in a sunlit room, would require further mitigation
to reduce background contamination of the signal for best
performance.
Given the above information about spectral contribution, the
ideal surgical room lighting would be white-light LEDs. The
PerkinElmer Solaris system performs background correction
by pulsing the excitation sources to sequentially image fluores-
cence emission and background light leakage to make on-line
corrections. It has been shown that systems that perform some
kind of background correction tend to perform better than those
without;54 this improvement in performance can also be seen
from the sensitivity and linearity tests data in Sec. 4.3.
4.3 High Sensitivity to Fluorophore of Interest and
Ability to Quantify In Situ
The concentrations of fluorescent agents in tissue vary by
orders of magnitude depending on their distribution and target-
ing to specific disease biomarkers. Nonspecific agents, such as
ICG, are usually administered intravenously and generally
remain in the tissue at concentrations in the low micromolar
range. Target-specific agents, on the other hand, are generally
given time to clear normal tissue, thus will usually be present
in midlow nanomolar concentrations in tissue. This poses a chal-
lenge when devices designed for ICG imaging are used to image
targeted probes, as the sensitivity limits are not always opti-
mized for low-concentration probes. All available systems
were evaluated for their ability to detect and quantify signals
from IRDye 800CW (LI-COR Biosciences, Lincoln, NE) in
phosphate-buffered saline, through the logarithmic concentra-
tion range from 3 pM to 25 μM. The samples were imaged
individually to allow the user to modify any available gain
and exposure settings and maximize the ability to detect
fluorescence emission. We grouped the systems into FDA-
approved imagers [Fig. 4(a)] and preclinical imagers [Fig. 4(b)].
Plots showing “log10ðfluorophore concentrationÞ” versus
“log10ðnormalized fluorescence signalÞ” are shown in Fig. 4.
A handful of imagers also performed imaging in the 700-nm
channel, so IRDye 680RD samples were used to evaluate
them. As a reference, the performance was compared to the
LI-COR Pearl Impulse preclinical imager, which provides
over 20-bits of dynamic range, and performs imaging in an
ambient-light-free chamber. Slopes of linear fits to the log–
log data (slope ¼ 1 for linearity on these log–log plots) and
the lowest detectable concentrations are shown in the table of
Fig. 4(d).
All imagers, under ideal conditions and dimmed lighting
were able to detect down to a surface concentration of
∼10 nM for both IRDye 800CW and IRDye 680RD (for dual-
channel systems that have this channel). Thus, per this criterion,
all systems seem suitable for imaging high concentrations of
ICG, as intended. For imaging lower concentrations of fluoro-
phores, it is observed that systems with higher bit depths,
variable electronic gain settings, and/or background-light
correction during acquisition had the best sensitivity. The
VisionSense Iridium system outperforms all other instruments
in terms of sensitivity to low concentrations owing to its high
camera bit depth and gain adjustment (1 to 200×) capability.
The Solaris was a close second in terms of sensitivity, again
due to the high bit depth and background correction function-
ality based on pulsing excitation light; but the lack of gain
adjustment likely limits its sensitivity below ∼1 nM. The
Fluobeam800 system with the ability to manually vary exposure
time could achieve sensitivity down to ∼5 nM, but this comes at
the expense of long-exposure times on the order of seconds,
which may not be feasible within a clinical setting. Similar sen-
sitivity is obtained with the Novadaq SPY system in real-time
video mode. The Quest Spectrum though equipped with a 14-bit
camera compresses the image data to 8-bits at the camera
output resulting in reduced sensitivity and dynamic range,
which severely affected the overall system performance. In
terms of quantitative ability, the closer a log–log fitted-slope
(Fit equation: log10 y ¼ m · log10 xþ C which is equivalent
to y ¼ 10C · xm, where m is the slope) was to 1, the more reli-
able a system could be for linear reporting of concentration,
which was seen well with the Solaris system, owing to
background correction. The Quest spectrum and VisionSense
Iridium devices utilize 14-bit and 12-bit cameras, respectively,
but ultimately map their data to 8-bit thus resulting in nonlinear
compression and an observed slope of <1. While VisionSense
uses smart image processing algorithms to produce a wide
dynamic range, the Quest Spectrum lacked such features, thus
the range of detection suffers, and sensitivity is about ∼10 nM.
It should be noted that for data from VisionSense and Fluobeam
fluorescence signal measurements were scaled by the gain set-
tings and exposure times, respectively. Aside from fluorescence
intensity, some systems, e.g., Novadaq SPY, may also provide
perfusion and flow rate as quantitative endpoints; these
measurements are usually made in software based on the fluo-
rescence intensity data, and would hence be affected by the lin-
earity and quantitative performance of the system as described
herein. Curadel’s Lab-Flare R1 was excluded from Fig. 4 as a
final commercial system was unavailable for testing at the time
of publishing this paper, although based upon the design
the sensitivity, it was expected to be comparable to the other
advanced systems and reported to be in the single nM range
or better. The SurgVision system was also excluded from Fig. 4
as the sensitivity tests on this system were not available in the
same methodology as used for all the other systems. However,
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the sensitivity to IRDye 800CW reported by the company is
∼60 pM, which would make it among the most sensitive of
the systems evaluated. This is most likely attributable to their
use of an EMCCD capable of single-photon detection.
4.4 Ability to Image Multiple Fluorophores
Simultaneously
Barring excitation sources and emission filters, a large part of
the optics and instrumentation of an imager is more or less in-
dependent of the fluorophore being imaged within the tolerance
limits on the optics. Some systems have been designed to house
excitation sources for multiple excitation wavelength bands
along with emission filter sets, to allow for multifluorophore im-
aging, either simultaneously or by switching between channels
using a filter wheel. This multichannel functionality certainly
adds to the cost of the device, but such a system can be a worthy
investment for a research group working with multiple imaging
agents, and combinations of targeted and untargeted tracers for
quantification of disease biomarkers.48 A total of three out of the
eight imagers we compared are capable of multiple fluorophore
imaging; the Curadel Lab-Flare R1 and the Quest Spectrum
can image in the ∼700- and ∼800-nm channels simultaneously,
while the Solaris is capable of imaging∼470-,∼660-,∼750-, and
∼800-nm channels independently (nonsimultaneous). Figure 2(d)
shows an example of simultaneous white-light, 700-, and 800-nm
fluorescence imaging with the merged display available on the
Flare imagers.
4.5 Maximized Ergonomic Use
As a general principle, compact, portable units are easier to
deploy in a surgical suite than large roll-in systems. However,
the computer, display monitors, and illumination unit contribute
significantly to the size and usability of a system. Studies have
shown that choice of display, their location, and setup can sig-
nificantly affect surgical tasks and their outcomes.56 Currently,
fluorescence-imaging systems are either compact, handheld
systems such as VisionSense Iridium, Fluobeam, and PDE Neo,
or larger, overhead, wheel-based systems with significant foot-
prints such as the Solaris and Curadel systems. The former do
provide mounting arms and carts to users who need them while
the latter can be large enough to need a 36- to 100-ft2 room for
storage. Stability of images and impact of vibrations vary among
devices, with larger heavier devices built for greater stability




















Fluobeam* 0.7 ~5nM 1.4 ~5nM
Solaris 0.9 ~1nM 0.7 ~75pM
Novadaq SPY 0.6 ~5nM - -
PDENeo 0.3 ~15nM - -
Quest spectrum 0.3 ~10nM 0.5 ~5nM
LI-COR pearl** 1 ~50pM 1 ~50pM





























































































Fig. 4 Plots of log10ðFluorophore ConcentrationÞ versus log10ðNormalized FluorescenceÞ are shown for
measurements of IRDye 800CW using FDA-approved imagers (a). Panel (b) shows IRDye 800CWmea-
surements on imagers that are not approved for clinical use. Measurements from the LI-COR pearl
impulse preclinical imager are shown for comparison. Note that large variability exists in dynamic
range and detection sensitivity among FDA-approved imagers. Panel (c) shows similar plots for all sys-
tems with far-red emission imaging capability when IRDye 680RD samples were tested. A handful of
imagers also performed imaging in the 700-nm channel, so IRDye 680RD was tested on these. In
(d), the fitted slopes and the lower limit of detection are shown. *Fluoptics has two distinct imagers,
Fluobeam700 and Fluobeam800, for imaging in the 700-nm and 800-nm emission bands, respectively.
**The Li-COR Pearl imager was included simply as a standard of linearity and sensitivity achievable
using an enclosed light-tight imager.
Journal of Biomedical Optics 080901-9 August 2016 • Vol. 21(8)
DSouza et al.: Review of fluorescence guided surgery systems: identification of key performance. . .
hardware. Figure 5 shows photographs of the various commer-
cial systems. Though not to exact scale, the systems can be com-
pared for size and physical footprint.
Handheld systems can provide better access to complex tis-
sue geometries, such as around the head and neck or inside
limbs, and are also highly mobile, whereas the larger systems
generally have a wide range of functionalities such as multiple
fluorophore capability, large FOV size, and large working dis-
tance. Both the PerkinElmer Solaris and Curadel Lab-Flare sys-
tem have a large range of FOV sizes over which focus errors
are minimal; the Lab-Flare in particular has been optimized to
maintain parfocality from 0.9 × 0.9 cm2 to 25 × 25 cm2 over
working distances from 12 to 18 in., enabling its usage in a
wide range of surgical applications. The appropriate working
distance depends directly on the intended usage, but it is inter-
esting to note that the Solaris is the only system with a fixed
working distance of 75 cm, which keeps the imaging head well
out of the way of a surgeon’s workspace. Along with the use
of multiple excitation angles, this system attempts to provide
a highly ergonomic solution to imaging fluorophores during
surgery, replacing the surgical light as well. Nevertheless, as
surgical applications are highly varied, ranging from inside the
abdominal cavity to under the armpit, there is no single optimal
design, and selecting a system will require careful consideration
of its intended use. With large FOV options available on some
systems, the image uniformity and quality across the field can be
an important factor to consider. Qualitatively, these aspects were
not significantly different across the large roll-in systems, but
the handheld devices designed with lightweight optics were of
acceptable but slightly poorer performance. This may or may not
be significant depending on the intended clinical application, but
could be important especially when fluorescence guidance is
being used to save or resect fine structures, such as nerves,
demanding high resolution and quality across the entire FOV.
5 Discussion
The very limited set of approved fluorophores and approved
procedures, and the lack of medical reimbursement codes in
the United States for fluorescence-guided surgery procedures
have kept the market for imagers in clinical imagers modest;
however, owing to the direct surgical impact of these systems
on surgical workflow, their overall demand continues to grow.
Due to the simplicity of design, most systems are specified for
operation only in the NIR-range to capture ICG emission in vessel
flow, since this use remains the only approved NIR fluorescence
procedure. Table 2 presents all commercially available open sur-
gery fluorescence imagers compared on the basis of the “key
desirable features” described in Sec. 4. A listing of technical
specifications is also provided in Table 3. In reviewing the sys-
tems presented here, we found that the Solaris is the only openly
marketed system with specifications well laid out, with the
capacity to image a wide range of fluorescence emission chan-
nels. While other instruments predominantly target the ICG
market, they cost about half of that of the Solaris and will be
important devices for imaging the other ∼800-nm agents that are
in various stages of preclinical and investigational new drug
development. Meanwhile, off-label use of approved fluorophores
has become increasingly common in sentinel lymph node map-
ping,57 tumor resection surgeries,58 and perfusion assessment,
while identification of disease in situ demands the use of target-
specific fluorophores.59 This is especially true in oncological
applications such as margin assessment and metastasis detection.
The development of new agents is driving technological
advances by increasing the demand for new systems with
lower sensitivity, shifted wavelengths, and more ergonomic
set of display and usage features. The adoption of fluorescence
guidance for surgery within research settings is well underway,
and several imaging instrument companies have identified them
as their initial target customers. This has led to emergence
of several systems such as Curadel ResVet Lab-Flare and
PerkinElmer Solaris that are not immediately seeking FDA
approvals, but rather targeting veterinary markets at the current
time. However, these systems present feature-rich capabilities
with significant benefits for imaging newer test agents. As
such, there is a small commercial market developing in some
areas for these research units, which will pave the way for future
Fig. 5 Images of the leading fluorescence guidance systems evaluated here, targeted for open surgery
use, shown with relative approximate size comparison. The PerkinElmer Solaris, Curadel ResVet Lab-
Flare, and SurgVision Explorer Air are not 510(k) cleared for human use, while the others are for ICG
procedures. All have capability to image ICG in surgical trials, with differing levels of sensitivity and fea-
tures. Images from left to right are from Solaris™ Open-Air Fluorescence Imaging System, Printed with
permission, (c)2015-2016 PerkinElmer, Inc., all rights reserved; NOVADAQ Spy-Elite™, copyright 2016
Novadaq Technologies Inc.; Quest Spectrum™, copyright Quest Medical Imaging; Fluobeam(R),
copyright 2016 Fluoptics; Hamamatsu PDE-Neo™; Lab-FLARE(R) Model R1 copyright CURADEL;
Visionsense Iridium™, copyright Visionsense; SurgVision Explorer Air prototype, image courtesy of
SurgVision. All images have been printed with permission from copyright holders.
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indications and potential FDA clearance applications. There are
also companies such as Quest Medical Imaging, Curadel, and
SurgVision that are designing high-end systems customizable
to the specific requirements of their research users through
industry-academic partnerships. The number of these non-
cleared systems will likely grow as the field of fluorescence-
guided surgical research develops.
In this study, ICG was not used for testing, since this
molecule is well known to be of low fluorescence yield and
unsuitable for specific binding to other proteins. The IRDye
candidates used here are only one set of possible agents, but
specifically IRDye 800CW is one that has been used in several
human clinical trials, and was specifically designed and sup-
ported for protein binding, while preserving the high molar
absorption coefficient and emission quantum yield. So while the
testing was completed for IRDyes 800CW and 680RD, other
candidate agents will have shifted spectra as well, and sensitivity
testing should be carried out as needed to validate the lower
level of sensitivity, as shown in the results here of Fig. 4. As
mentioned above though, the linearity results here are likely
universal, while a shift in the spectrum of the dye would typi-
cally affect only the lower-level sensitivity limit.
In the near-term, it should be expected that several new sys-
tems will be launched in the coming months, including the
SurgVision imager, which is similar in optical-filtering design
to the Lab-Flare instrument but uses a single EMCCD-based
fluorescence camera and customizable emission filters. All com-
mercial multispectral fluorescence imagers are still in a preclini-
cal development phase and the exact FDA clearance trajectory
for these systems is not yet clear. This new trend in development
of customizable systems built to user specifications with flexi-
bility in choice of excitation and emission wavelengths will
likely have its own trajectory, with leading research users seek-
ing local institutional review board approvals for research use,
allowing the use of more fully featured systems in a trial, rather
than waiting for an FDA-cleared versions with fixed specifica-
tions. This will certainly impact the drug discovery and develop-
ment processes. In the long term, it should be expected that a fair
amount of reorganization and consolidation could occur, as
the industry converges on what the eventual demands will be
from a clinical point of view, and based on what is needed for
further research and development. To date, with the exception of
PerkinElmer, the larger imaging companies have remained on
the sideline in the open surgery area. Notable exceptions are the
advances of Olympus, Leica, and Zeiss in other surgical special-
ties such as endoscopy and neurosurgery. However, the special-
ized systems will likely reach a level of success first through
510(k) clearance for conventional ICG imaging and likely be
used off-label for clinical research in agents for open surgery.
This process is happening now, and these more feature-rich sys-
tems will lead to an industry specialization around the indications
that have the most clinical adopters and most promising trials.
6 Conclusions
In summary, a proposed set of “desirable features” has been
described, in descending order of importance; these are sug-
gested to be the right judgment criteria for evaluating a fluores-
cence-imaging device for open-surgical use. These criteria and
the results of the analysis are based on extensive testing and
evaluation of each FDA-approved and preclinical imager pre-
sented here. Real-time fluorescence overlay on RGB white-
light images and fluorescence-mode operation under ambient
room lighting are proposed as the most important requirements
because these aspects limit the utility of a system if not present,
irrespective of its sensitivity. Sensitivity to low fluorophore con-
centrations and the ability to linearly quantify relative fluoro-
phore concentrations are next most important in rank order, as
these will ultimately determine the clinical use of the imaging
device. Furthermore, as the adoption of fluorescence imaging to
guide surgery continues to grow, the quantitative ability will
play an important role in comparing data from multicenter trials,
and comparing results spatially and longitudinally both within
and among patients. Next, simultaneous multifluorophore imag-
ing capability is an “extra” feature to most users but can be criti-
cal for research laboratories developing next-generation imaging
agents and methods to improve cancer extent and margin
assessment using combinations of imaging agents. Lastly, we
discussed ergonomics as the final important criterion for select-
ing a system, as this is again greatly tied to system utility during
surgery. While we have proposed this set of desirable features,
each system does come with its own set of positive and negative
aspects and there is no single “best” system in the market. The
intention of this review paper is to help simplify the task of
selecting the right system to invest in for both translational clini-
cal trials and preclinical or veterinary research
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